MMP23B: A Protein Target for Tissue Repair and Regeneration (G8510)

Target Name: MMP23B

NCBI ID: G8510

MMP23B

MMP23B: A Protein Target for Tissue Repair and Regeneration

Matrix metalloproteinase (MMP) 23B (MMP23B) is a protein that is expressed in various tissues throughout the body, including the extracellular matrix (ECM), bone, and soft tissues. MMP23B is a member of the MMP family of proteins, which are involved in the degradation of extracellular matrix proteins and other cell-surface components.

MMP23B has been shown to play a role in the regulation of cellular processes that are important for tissue repair and regeneration, such as bone growth and wound healing. It has also been shown to be involved in the development and progression of various diseases, including cancer and neurodegenerative diseases.

Due to its involvement in these processes, MMP23B has been identified as a potential drug target for a variety of diseases. Researchers have found that MMP23B is often overexpressed or hyperactive in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, MMP23B has also been shown to be a potential biomarker for a variety of diseases. Its expression has been shown to be associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential benefits of targeting MMP23B as a drug or biomarker is its potential to treat a variety of diseases that are currently un treatable or have limited treatment options. For example, MMP23B has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Targeting MMP23B with small molecules or other therapeutic agents has been shown to have potential therapeutic benefits in these conditions.

Another potential benefit of targeting MMP23B is its potential to improve the effectiveness of existing treatments. For example, MMP23B has been shown to play a role in the development and progression of cancer, and targeting it with therapeutic agents has been shown to improve the effectiveness of chemotherapy and other treatments.

In addition to its potential therapeutic and biomarker applications, MMP23B also has potential structural and biochemical properties that make it an attractive target for study. Researchers have shown that MMP23B is involved in the regulation of cellular processes that are important for its structure and function, including cell adhesion, migration, and invasion.

Furthermore, MMP23B has been shown to have multiple interacting partners, including other proteins and factors that have been shown to play important roles in its regulation. These interactions may provide new insights into the mechanisms of MMP23B action and may have implications for the development of new therapeutic approaches.

Overall, MMP23B is a protein that has significant potential as a drug target and biomarker. Its involvement in the regulation of cellular processes that are important for tissue repair and regeneration, as well as its association with the development and progression of various diseases, make it an attractive target for study. Further research is needed to fully understand the mechanisms of MMP23B action and to develop new therapeutic approaches.

Protein Name: Matrix Metallopeptidase 23B

Functions: Protease. May regulate the surface expression of some potassium channels by retaining them in the endoplasmic reticulum (By similarity)

The "MMP23B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMP23B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets